Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation
The crown jewel of a multibillion-dollar Novartis acquisition has won a new endorsement from the FDA, and it’s a program at the forefront of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
